Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

List of selective estrogen receptor modulators

From Wikipedia, the free encyclopedia
(Redirected fromList of SERMs)

Tamoxifen, a triphenylethylene derivative and the most well-known and widely used SERM.

This is a list ofselective estrogen receptor modulators (SERMs).

Approved

[edit]

SERMs that have been approved for medical use includeanordrin (+mifepristone (Zi Yun)),bazedoxifene (+conjugated estrogens (Duavee)),broparestrol (Acnestrol),clomifene (Clomid),cyclofenil (Sexovid),lasofoxifene (Fablyn),ormeloxifene (Centron, Novex, Novex-DS, Sevista),ospemifene (Osphena; deaminohydroxytoremifene),raloxifene (Evista),tamoxifen (Nolvadex), andtoremifene (Fareston; 4-chlorotamoxifen).[1]

Clinical trials

[edit]

SERMs that are currently under development and in clinical trials includeacolbifene,afimoxifene (4-hydroxytamoxifen; metabolite of tamoxifen),elacestrant,enclomifene ((E)-clomifene),endoxifen (4-hydroxy-N-desmethyltamoxifen; metabolite of tamoxifen), andzuclomifene ((Z)-clomifene).[2]

Non-approved

[edit]

SERMs that have not been approved for medical use includearzoxifene,brilanestrant,clomifenoxide (clomiphene N-oxide; metabolite of clomifene),[3]droloxifene (3-hydroxytamoxifen),etacstil,fispemifene,GW-7604 (4-hydroxyetacstil; metabolite of etacstil),idoxifene (pyrrolidino-4-iodotamoxifen),levormeloxifene ((L)-ormeloxifene),miproxifene,nafoxidine,nitromifene (CI-628),NNC 45-0095,panomifene,pipendoxifene (ERA-923),trioxifene, andzindoxifene (D-16726).[4][1][5][6][7]

Sivifene (A-007) was initially thought to be a SERM due to its structural similarity to tamoxifen but it was subsequently found not to bind to theestrogen receptor (ER).[8]Tesmilifene (DPPE; YMB-1002, BMS-217380-01) is also structurally related to tamoxifen but similarly does not bind to the ER and is not a SERM.[9][10]

Structure

[edit]

SERMs can be variously classifiedstructurally astriphenylethylenes (tamoxifen, clomifene, toremifene, droloxifene, idoxifene, ospemifene, fispemifene, afimoxifene, others),benzothiophenes (raloxifene, arzoxifene),indoles (bazedoxifene, zindoxifene, pipendoxifene),tetrahydronaphthalenes (lasofoxifene, nafoxidine), andbenzopyrans (acolbifene, ormeloxifene, levormeloxifene).[11][12][13]

References

[edit]
  1. ^abPinkerton, JoAnn V.; Thomas, Semara (2014). "Use of SERMs for treatment in postmenopausal women".The Journal of Steroid Biochemistry and Molecular Biology.142:142–154.doi:10.1016/j.jsbmb.2013.12.011.ISSN 0960-0760.PMID 24373794.S2CID 24196362.
  2. ^"Home - AdisInsight".adisinsight.springer.com.
  3. ^Analytical Profiles of Drug Substances and Excipients. Academic Press. 20 March 1998. pp. 112–113.ISBN 978-0-08-086120-3.
  4. ^World Health Organization (2013),The use of stems in the selection of International Nonproprietary Names (INN)for pharmaceutical substances(PDF)
  5. ^J. Elks (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer.ISBN 978-1-4757-2085-3.
  6. ^I.K. Morton; Judith M. Hall (6 December 2012).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media.ISBN 978-94-011-4439-1.
  7. ^Taylor, Hugh S. (2009)."Designing the ideal selective estrogen receptor modulator-an achievable goal?".Menopause.16 (3):609–615.doi:10.1097/gme.0b013e3181906fa3.ISSN 1072-3714.PMC 3107842.PMID 19182697.
  8. ^Eilender, David; LoRusso, Patricia; Thomas, Leonard; McCormick, Catherine; Rodgers, Andrew H.; Hooper, Catherine L.; Tornyos, Karl; Krementz, Edward T.; Parker, Steven; Morgan, Lee Roy (2005). "4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers".Cancer Chemotherapy and Pharmacology.57 (6):719–726.doi:10.1007/s00280-005-0124-2.ISSN 0344-5704.PMID 16184382.S2CID 10830366.
  9. ^Brandes LJ (2008)."N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer".Hum Exp Toxicol.27 (2):143–7.doi:10.1177/0960327108090751.PMID 18480139.S2CID 20966915.
  10. ^Brandes LJ, Hermonat MW (1984). "A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes".Biochem. Biophys. Res. Commun.123 (2):724–8.doi:10.1016/0006-291x(84)90289-4.PMID 6548377.
  11. ^John P. Bilezikian; Lawrence G. Raisz; T. John Martin (29 September 2008).Principles of Bone Biology. Academic Press. pp. 891–.ISBN 978-0-08-056875-1.
  12. ^Stuart Silverman; Bo Abrahamsen (29 December 2015).The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy. Springer. pp. 24–.ISBN 978-3-319-23639-1.
  13. ^Atta-ur Rahman; Khurshid Zaman (28 November 2014).Topics in Anti-Cancer Research. Bentham Science Publishers. pp. 559–565.ISBN 978-1-60805-908-9.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_selective_estrogen_receptor_modulators&oldid=1217574814"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp